Heghine Khachatryan: New Evidence in Secondary Stroke Prevention: Cilostazol + Aspirin vs Ticagrelor + Aspirin
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by International Journal of Stroke on LinkedIn:
“New evidence in secondary stroke prevention
A recent study published in the International Journal of Stroke reports that cilostazol plus aspirin significantly reduces recurrent stroke, myocardial infarction, and vascular death, with comparable efficacy to ticagrelor plus aspirin in the acute-phase treatment of large-vessel disease.
Why this matters
• Provides an alternative dual antiplatelet strategy with proven effectiveness
• Particularly relevant for patients with high bleeding risk, intolerance, or contraindications to potent P2Y12 inhibitors
• Highlights the growing role of cilostazol-based regimens beyond East Asian populations
-This study adds valuable data to ongoing discussions on individualized antiplatelet therapy after ischemic stroke and reinforces the need to balance efficacy with safety.
Full article: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel disease”
Quoting International Journal of Stroke‘s post:
“Study finds cilostazol plus aspirin reduced recurrent stroke, MI, and vascular death with a comparable rate to ticagrelor plus aspirin
However, cilostazol plus aspirin showed significantly lower rates of hemorrhagic complications and better tolerability
Read more here.”
Title: Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial
Authors: Mohamed Ismaiel, Sherihan Rezk ahmed et al.
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jul 18, 2026, 14:54Fabien Mselati: Reflecting on 25 Years of Hemophilia Progress
-
Jul 18, 2026, 14:50Nikola Pantic: Grateful for the People Who Made ISTH 2026 Special
-
Jul 18, 2026, 14:30Denise Rezende: Werfen Reflects on a Successful ISTH 2026 Congress
-
Jul 18, 2026, 14:28Isabelle Salles-Crawley: Science, Collaboration, and Inspiration at ISTH 2026
-
Jul 18, 2026, 14:05Habib Bennaceur: Novo Nordisk Highlights Progress in Rare Bleeding Disorders at ISTH 2026
-
Jul 18, 2026, 13:56C. Heleen van Ommen: IPTN Meeting Highlights Progress in Pediatric Thrombosis
-
Jul 18, 2026, 13:42Chokri Ben Lamine: Optimizing PBSC Donation in Hemoglobinopathy Carriers
-
Jul 18, 2026, 12:17Doruntina Lahu: Prasugrel and Ticagrelor – Does Sex Matter?
-
Jul 18, 2026, 11:54Paul Riley: Presenting STAR Max3 at ISTH 2026